1
|
Jeremic J, Govoruskina N, Bradic J, Milosavljevic I, Srejovic I, Zivkovic V, Jeremic N, Nikolic Turnic T, Tanaskovic I, Bolevich S, Jakovljevic V, Bolevich S, Zivanovic MN, Okwose N, Seklic D, Milivojevic N, Grujic J, Velicki L, MacGowan G, Jakovljevic DG, Filipovic N. Sacubitril/valsartan reverses cardiac structure and function in experimental model of hypertension-induced hypertrophic cardiomyopathy. Mol Cell Biochem 2023; 478:2645-2656. [PMID: 36997815 DOI: 10.1007/s11010-023-04690-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Accepted: 02/24/2023] [Indexed: 04/01/2023]
Abstract
This study evaluated the effect of sacubtril/valsartan on cardiac remodeling, molecular and cellular adaptations in experimental (rat) model of hypertension-induced hypertrophic cardiomyopathy. Thirty Wistar Kyoto rats, 10 healthy (control) and 20 rats with confirmed hypertension-induced hypertrophic cardiomyopathy (HpCM), were used for this study. The HpCM group was further subdivided into untreated and sacubitril/valsartan-treated groups. Myocardial structure and function were assessed using echocardiography, Langendorff's isolated heart experiment, blood sampling and qualitative polymerase chain reaction. Echocardiographic examinations revealed protective effects of sacubitril/valsartan by improving left ventricular internal diameter in systole and diastole and fractional shortening. Additionally, sacubitril/valsartan treatment decreased systolic and diastolic blood pressures in comparison with untreated hypertensive rats. Moreover, sacubitril/valsartan treatment reduced oxidative stress and apoptosis (reduced expression of Bax and Cas9 genes) compared to untreated rats. There was a regular histomorphology of cardiomyocytes, interstitium, and blood vessels in treated rats compared to untreated HpCM rats which expressed hypertrophic cardiomyocytes, with polymorphic nuclei, prominent nucleoli and moderately dilated interstitium. In experimental model of hypertension-induced hypertrophic cardiomyopathy, sacubitril/valsartan treatment led to improved cardiac structure, haemodynamic performance, and reduced oxidative stress and apoptosis. Sacubitril/valsartan thus presents as a potential therapeutic strategy resulted in hypertension-induced hypertrophic cardiomyopathy.
Collapse
Affiliation(s)
- Jovana Jeremic
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
| | - Natalia Govoruskina
- Federal Clinical Center for High Medical, Technologies Federal Health Biological Agency, Moscow, Russia
| | - Jovana Bradic
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
| | - Isidora Milosavljevic
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
| | - Ivan Srejovic
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
- Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia
- Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vladimir Zivkovic
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
- Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia
- Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Nevena Jeremic
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
- I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Tamara Nikolic Turnic
- Department of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia
- F.F. Erismann Institute of Public Health, N.A. Semashko Public Health and Healthcare Department, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Irena Tanaskovic
- Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
| | - Stefani Bolevich
- Department of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
- Department of Pathophysiology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Vladimir Jakovljevic
- Center of Excellence for Redox Balance Research, Cardiovascular and Metabolic Disorders, Kragujevac, Serbia.
- Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, 34000, Kragujevac, Serbia.
- Department of Human Pathology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
| | - Sergey Bolevich
- Department of Human Pathology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
| | - Marko N Zivanovic
- Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia
- BioIRC - Bioengineering Research and Development Center, University of Kragujevac, Kragujevac, Serbia
| | - Nduka Okwose
- Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
| | - Dragana Seklic
- Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia
| | - Nevena Milivojevic
- Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia
| | - Jelena Grujic
- Institute for Information Technologies Kragujevac, University of Kragujevac, Kragujevac, Serbia
| | - Lazar Velicki
- Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
- Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
| | - Guy MacGowan
- Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
| | - Djordje G Jakovljevic
- Translational and Clinical Research Instutute, Faculty of Medical Sciences, Newcastle University and Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK
- Faculty Research Centre (CSELS), Faculty of Health and Life Sciences, Institute for Health and Wellbeing (CSELS), Coventry University, London, UK
| | - Nenad Filipovic
- BioIRC - Bioengineering Research and Development Center, University of Kragujevac, Kragujevac, Serbia
- Faculty of Engineering, University of Kragujevac, Kragujevac, Serbia
| |
Collapse
|
2
|
Lanthier ML, Kerr KW, Miller KL. An Analysis of Follow-On Development in New Drug Classes, January 1986-June 2018. Clin Pharmacol Ther 2019; 106:1125-1132. [PMID: 31206617 DOI: 10.1002/cpt.1554] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Accepted: 05/13/2019] [Indexed: 11/11/2022]
Abstract
Follow-on drugs-new medicines approved within an established drug class-provide incremental treatment improvements, additional choices for clinicians and patients, and potential price competition. We examine the timing, quantity, and product characteristics of within-class drug approvals for new drug classes approved by the US Food and Drug Administration since January 1986. We find that nearly two-thirds of first-in-class drugs do not face a subsequent follow-on product. Follow-on innovation within a drug class was more common and occurred more rapidly in the 1990s than during the 2000s. We also find that fewer drug classes have multiple competitors entering the market during the 2000s. First-in-class drugs treating rare disorders experienced lower rates of follow-on entry than drugs treating common medical conditions. The decreased pace of follow-on development likely results from greater industry focus on rare diseases and increasing reimbursement pressure on products lacking clear advantages over existing products.
Collapse
Affiliation(s)
- Michael L Lanthier
- Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Kirk W Kerr
- Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
| | - Kathleen L Miller
- Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland, USA
| |
Collapse
|